


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

SUPPLEMENTAL INFORMATION DISCLOSURE TRANSMITTAL

In re Application of: William F. Kaemmerer
For: Treatment of Neurodegenerative Disease through Intracranial Delivery of siRNA
Serial No.: 10/721,693
Filed: November 25, 2003



CERTIFICATE OF MAILING DATE OF DEPOSIT

6-27-05

I hereby certify that this paper is being deposited with the U.S. Postal Service, as First Class Mail under 37 CFR 1.10 on the date indicated above and addressed to the Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Juanita I. Traufler
Juanita I. Traufler

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Enclosed for filing in the above-identified application are the following:

- ☒ Supplemental Information Disclosure Transmittal
- ☒ Supplemental Information Disclosure Statement
- ☒ PTO Form 1449
- ☒ Copies of Cited Reference:
(DE 19910340 Abstract)
- ☒ Return postcard

Accompanying this Transmittal is the \$180.00 fee set forth in 37 C.F.R. §1.17(p) for submission of an Information Disclosure Statement under §1.97(c).


- ☒ The Commissioner is hereby authorized to charge or credit any deficiencies or overpayments, that may have been overlooked on this Transmittal with regard to this filing, to Deposit Account No. 13-2546. A duplicate of this Transmittal is enclosed.

Respectfully submitted for,

Kaemmerer, et al.

Kenneth J. Collier
Kenneth J. Collier
Reg. No. 34,982
CUSTOMER NUMBER 27581
Telephone: (763) 505-2521

June 22, 2005
Date



PATENT

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: William F. Kaemmerer

Serial No: 10/721,693

Filed: November 25, 2003


Docket: P-11089.00

Title: Treatment of Neurodegenerative Disease through Intracranial Delivery of siRNA

CERTIFICATE OF MAILING

DATE OF DEPOSIT 6-27-05

I hereby certify that this paper is being deposited with the U.S. Postal Service, as First Class Mail, addressed to the Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Juanita I. Trautler

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

In compliance with the duty of disclosure under 37 C.F.R. §1.56, and in accordance with the practice under 37 C.F.R. §1.97 and §1.98, the Examiner's attention is directed to the documents listed on the enclosed modified Form PTO-1449. No inference should be made that the cited references are in fact material, are in fact prior art, or that no better art exists. The cited patents are listed in numerical order and are not in any order based on their pertinence.

The above-identified application was filed after June 30, 2003. Therefore, pursuant to the waiver of the requirement under 37 C.F.R. 1.98(a)(2)(i) as stated in a Pre-OG Notice dated July 11, 2003, copies of only the foreign patent documents and non-patent literature listed on the enclosed Form PTO-1449 are attached.

This Supplemental Information Disclosure Statement is being filed within three months of the United States filing date or before the mailing date of a first Office Action on the merits. No certification or fee is required (37 C.F.R. §1.97). Foreign patent document


The Commissioner is hereby authorized to charge any additional fees which may be required or credit any overpayment to Deposit Account 13-2546.

It is respectfully requested that the above information be considered by the Examiner and that a copy of the enclosed Form PTO-1449 be returned indicating that such information has been considered.

Respectfully submitted for,
Kaemmerer, et al.

By: 

Kenneth J. Collier
Registration No. 34,982
CUSTOMER NUMBER 27581
Telephone (763) 505-2521

INFORMATION DISCLOSURE STATEMENT 	Atty Docket No:	P11089.00	Serial No.:	10/721,693
	Applicant(s): William F. Kaemmerer			
	Filing Date:	25-Nov-03	Group:	0

US PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name of Patentee or Applicant of Cited Document	Class	SubClass	Filing Date If Appropriate
	US 2001/0027309 A1	04-Oct-01	Elsberry, Dennis D.			01-Jun-01
	US 2002/0068093 A1	06-Jun-02	Trogolo, Jeffrey A., et al	424/618		29-Aug-01
	US 4683195	28-Jul-87	Mullis, Kary B., et al	435/6		07-Feb-86
	US 4683202	28-Jul-87	Mullis, Kary B.	435/91		25-Oct-85
	US 4800159	24-Jan-89	Mullis, Kary B., et al	435/172.3		17-Dec-86
	US 4965188	23-Oct-90	Mullis, Kary B. et al	435/6		17-Jun-87
	US 5354326	11-Oct-94	Comben, Richard H. et al	607/115		27-Jan-93
	US 5624803	29-Apr-97	Noonberg, Sarah et al	435/6		13-Oct-94
	US 5720720	24-Feb-98	Laske, et al.	604/49		15-Mar-96
	US 5735814	07-Apr-98	Elsberry, Dennis D. et al.	604/43		30-Apr-96
	US 5782892	21-Jul-98	Castle, Vernon P. et al	607/37		25-Apr-97
	US 5814014	29-Sep-98	Elsberry, Dennis D., et al.	604/43		29-Jul-97
	US 6042579	28-Mar-00	Elsberry, Dennis D., et al.	604/891.1		30-Apr-97
	US 6093180	25-Jul-00	Elsberry, Dennis D.	604/506		18-Aug-97
	US 6180613	30-Jan-01	Kaplitt, et al.	514/44		06-Jun-95
	US 6187906	13-Feb-01	Gluckman, et al.	530/331		15-Jun-99
	US 6245884	12-Jun-01	Hook, Vivian Y.H.	530/300		16-Oct-98
	US 6281009	28-Aug-01	Boyce, Frederick M.	435/321.0		11-Sep-97
	US 6300539	09-Oct-01	Morris, Christopher M.	800/9		
	US 6310058	30-Oct-01	Miller, et al.	514/212.08		25-May-00
	US 6313268	06-Nov-01	Hook, vivian Y.H.	530/350		20-Apr-99
	US 6319905	20-Nov-01	Mandel, et al.	514/44		19-May-99
	US 6343233 B1	29-Jan-02	Werner, Robert I., et al	607/119		09-Sep-98
	US 6372721	16-Apr-02	Neuman, et al.	514/44		30-Sep-99
	US 6376471	23-Apr-02	Lawrence, III, et al.	514/44		08-Oct-98
	US 6436392	20-Aug-02	Engelhardt, et al.	424/93.2		25-Mar-99
	US 6468524	22-Oct-02	Chiorini, John A.	424/93.21		22-Mar-00
	US 6551290	22-Apr-03	Elsberry, et al.			31-Mar-00
	US 6594880	22-Jul-03	Elsberry, Dennis			23-May-01

EXAMINER	Date Considered
<p>Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p> <p>* - Reference Previously cited and provided to the Examiner.</p> <p>+ - New Reference not previously cited (available copies included).</p>	

FOREIGN PATENT DOCUMENTS

Examiner Initial	+/*	Document Number	Date	Name	Class	SubClass	Filing Date If Appropriate
		DE19910340	21-Sep-00	Froelich, J.C., (English Abstract)			
		WO 00/30567	02-Jun-00	Healthshield Technologies, Inc.			16-Nov-99
		WO 00/64505	02-Nov-05	Healthshield Technologies, L.L.C.			27-Apr-00
		WO 01/16312A2	08-Mar-01	Ribozyme Pharmaceuticals, Inc.	C12N 15/11		30-Aug-00
		WO 01/49844 A1	12-Jul-01	Rutgers, The State Univ of NJ	C12N 15/11		02-Jan-01
		WO 01/60794A2	23-Aug-01	The Regents of the Univ of CA	C07D		20-Feb-01
		WO 01/91801 A2	06-Dec-01	Chiron Corporation	A61K 48/00		25-May-01
		WO 03/047676 A1	12-Jun-03	Medtronic, Inc.	A61M 25/00		26-Nov-02
		WO 03/053516 A1	03-Jul-03	Medtronic, Inc.	A61N 1/375		18-Dec-02
		WO 03/070895 A2	28-Aug-03	Ribozyme Pharmaceuticals	C12N		18-Feb-03
		WO 03/099298 A1	04-Dec-03	Max-Planck Gesellschaft Zur Forderung Der Wissenschaften E.V.	A61K 31/7105		26-May-03
		WO 93/23569	25-Nov-93	Ribozyme Pharmaceuticals, Inc.	C12Q 1/68		29-Apr-93
		WO 94/02595	03-Feb-94	Ribozyme Pharmaceuticals, Inc.	C12N 5/22		02-Jul-93
		WO 9618736	20-Jun-96	Ribozyme Pharmaceuticals, Inc.	C12N 15/52		22-Nov-95
		WO 97/40874	06-Nov-97	Medtronic, Inc.	A61M 5/172, 5/173		30-Apr-97
		WO 99/50300A1	07-Oct-99	The Trustees of the Univ of PA	C07K 16/00		29-Mar-99
		WO2004/084955	07-Oct-04	Medtronic, Inc.			18-Mar-04
		WO2004/101063	25-Nov-04	Medtronic, Inc.			08-Mar-04
		WO2004041101	21-May-04	Medtronic, Inc.			27-Oct-03

OTHER DOCUMENTS (Including Authors, title, Date, Pertinent Papers, etc.)

Examiner Initial	+/*	Document Cite
		Aebischer, Patrick, Recombinant proteins for neurodegenerative diseases: the delivery issue, TRENDS in Neurosciences, Vol 24, No. 9, September 2001 pp 533-540

EXAMINER	Date Considered
<p>Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p> <p>* - Reference Previously cited and provided to the Examiner.</p> <p>+ - New Reference not previously cited (available copies included).</p>	

Based on Form PTO-FB-A820
(Also form PTO-1449)

Patent and Trademark Office, U.S. Department of Commerce

	Caplen, Natasha J., et al., Rescue of polyglutamine-mediated cytotoxicity by double-stranded RNA-mediated RNA interference, Human Molecular Genetics 11(2): 175-184 (2002)
	Chen et al., Multitarget-ribozyme directed to cleave at up to nine highly conserved HIV-1 env RNA regions inhibits HIV-1 replication—potential effectiveness against most presently sequenced HIV-1 isolates, Nucleic Acids Res., 20, 4581-4589, (1992)
	Chowrira et al., In vitro and in vivo comparison of Hammerhead, Hairpin and Hepatitis delta Virus Self-Processing Ribozyme Cassettes, Journal Biol. Chemistry, 269, pp 25856 - 25863 (1994)
	Clark, H., et al., Purkinji Cell Expression of a Mutant Allele of SCA1 in transgenic mice leads to disparate effects on motor behaviors, followed by a progressive cerebellar dysfunction and histological alterations, Journal of Neuroscience Vol 17 No. 19: pp 7385-7395 (1997)
	Couture et al., Anti-gene therapy; the use of ribozymes to inhibit gene function, Trends in Genetics, 12(12); 510-515 (Dec, 1996)
	Davidson, Beverly L., Molecular medicine for the brain: silencing of disease genes with RNA interference, The Lancet Neurology, Vol 3, March 2004, pp 145-149
	Dropulic et al., Functional characterization of a U5 Ribozyme: Intracellular Suppression of Human Immunodeficiency virus Type 1 Expression, Journal Virology., 66(1), 1432-1441 (1992)
	Glorioso, Joseph C., Use of HSV vectors to modify the nervous system, Current Opinion in Drug Discovery & Development 2002 5(2): PharmaPress Ltd ISSN 1367-6733
	Good, et al., Expression of small, therapeutic RNAs in human cell nuclei, Gene Therapy, (1997) Vol. 4, No. 45 - 54
	Goto, J., et al., Suppression of Huntingtin Gene Expression by siRNA: A Possible therapeutic Tool for Huntington's Disease, Neurology, Lippincoll Williams 7 Wilkins, Philadelphia, US, 60(5) Suppl 1, March 11 2003 p.A286
	Hommel, J.D., et al., Local gene knockdown in the brain using viral-mediated RNA interference, Society for Neuroscience Abstract Viewer and Itinerary Planner 2003, Vol 2003, Abstract No. 325.14, November 8-12, 2003
	Izant, Jonathan G., et al., Constitutive and Conditional Suppression of Exogenous and Endogenous Genes by Anti-Sense RNA, Science Vol 229, pp 345 (1985)
	Kaemmerer, W.F. and Puram, S., The potential for allele-specific reduction of ataxin1 expression using small, interfering RNA,
	Kashani-Sabet et al., Reversal of the Malignant Phenotype by an Anti-ras Ribozyme, Antisense Res. Dev., 2:3-15 (1992)
	Kitabwalla, Moiz, Ph.D., et al., RNA interference - a new weapon against HIV and beyond, New England Journal of Medicine, 347(17), (Oct 24 2002) pp 1364-1367
	Klement, Ivan, et al., Ataxin-1 nuclear localization and aggregation: Role in polyglutamine-induced disease in SCA1 transgenic mice, Cell Vol. 95: pp 41-53 (1998)
	L'Huillier, Phillip J., et al., Cytoplasmic delivery of ribozymes leads to efficient reduction in x-lactalbumin mRNA levels in C1271 mouse cells, EMBO Journal, Vol. 11, pp 4411-4418, No. 12 (1992)
	Lisiewicz et al., Inhibition of human immunodeficiency virus type 1 replication by regulated expression of a polymeric Tat activation response RNA decoy as a strategy for gene therapy in AIDS, Proc. National Acad Sci USA, Vol 90, pp 8000-8004, (Sept. 1993)

EXAMINER	Date Considered
<p>Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p> <p>* - Reference Previously cited and provided to the Examiner.</p> <p>+ - New Reference not previously cited (available copies included).</p>	

		Matilla, A., et al., Mice lacking ataxin-1 display learning deficits and decreased hippocampal paired-pulse facilitation, Journal of Neuroscience Vo. 18: pp 5508-5516 (1998) No. 14
		McGarry, Thomas J., et al., Inhibition of heat shock protein synthesis by heat-inducible antisense RNA, Proc. National Academy Science, USA Vol 83, pp 399, Jan. 1986
		McManus, Michael T., Gene Silencing in Mammals by Small Interfering RNAs, Nature Reviews / Genetics, Vol. 3 October 2002, pp737-747
		Miller, Victor M., Allele-specific silencing of dominant disease genes, PNAS, June 10, 2003, Vol. 100, No. 12, pp 7195-7200
		Naldini, Luigi, Efficient transfer, integration and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector, Proc. National Academy Science, Vol. 93, pp 11382-11388, October 1996
		Noonberg, et al., In vivo generation of highly abundant sequence-specific oligonucleotides for antisense and triplex gene regulation, Nucleic Acid Research, Vol. 22, pp 2830 - 2836, No. 14 (1994)
		Ohkawa, et al., Activities of HIV-RNA targeted ribozymes transcribed from a shot-gun type ribozyme-trimming plasmid, Nucleic Acids Symp. Ser., 27, pp 15-16, (1992)
		Ojwang, Joshua O., et al., Inhibition of human immunodeficiency virus type-1 expression by a hairpin ribozyme, Proc. National Academy Science USA, Vol 89, pp 10802-10806 (1992)
		Sarver, Nava et al., Ribozymes as potential anti-HIV-1 therapeutic agents, Science (1990) Vol. 247, pp 1222-1225
		Scanlon, K.J., et al., Ribozyme-mediated cleavage of c-fos mRNA reduces gene expression of DNA synthesis enzymes and metallothionein, Proc. National Academy Science USA, 88, (1991) 10591-10595
		Sullenger, Bruce and Cech, Thomas R., Tethering Ribozymes to a Retroviral Packaging Signal for Destruction of Viral RNA, Science, Vol. 262, p 1566 (12/03/1993)
		Taira et al., Construction of a Novel RNA-transcript-trimming Plasmid which can be used both In vitro in Place of Run-off and (G)-free Transcriptions and in vivo as Multi-sequences Transcription Vectors, Nucleic Acids Res., 19(19), p. 5125-5130 (1991)
		Thompson, James D., et al., Improved accumulation and activity of ribozymes expressed from a tRNA-based RNA polymerase III promoter, Nucleic Acids Res., (1995) Vol 23, pp 2259, No. 12
		Ventura et al., Activation of HIV-specific Ribozyme Activity by Self-Cleavage, Nucleic Acids Res., 21(14); 3249-3255, (1993)
		Weerasinghe, Migara et al., Resistance to human immunodeficiency virus type 1 (HIV-1) infection in human CD4 lymphocyte-derived cell lines conferred by using retroviral vectors expressing an HIV-1 RNA-specific ribozyme, Journal of Virology, Vol 65, pp 5531-5534, No. 10 (1991)
		Xia, et al., siRNA-mediated gene silencing in vitro and in vivo, Nature Biotechnology 20: pp 1006-1010 (Oct. 2002)
		Yamamoto, A, et al., Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's Disease, Cell Vol. 101: pp 57-66 (2000)
		Yu et al., A hairpin ribozyme inhibits expression of diverse strains of human immunodeficiency virus type 1, Proc. Natl. Acad. Sci. USA, Vol 90, pp 6340-6344 (July 1993)

EXAMINER	Date Considered
<p>Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p> <p>* - Reference Previously cited and provided to the Examiner.</p> <p>+ - New Reference not previously cited (available copies included).</p>	

		Yu, Jenn-Yah et al., RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells, PNAS, April 30, 2002, Vol. 99, No. 9, pp 6047-6052
--	--	---

EXAMINER	Date Considered
<p>Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p> <p>* - Reference Previously cited and provided to the Examiner.</p> <p>+ - New Reference not previously cited (available copies included).</p>	

Based on Form PTO-FB-A820
(Also form PTO-1449)

Patent and Trademark Office, U.S. Department of Commerce